Novartis: FDA accepts sickle cell disease drug for review
(CercleFinance.com) - Novartis said on Tuesday its investigational drug for sickle cell disease has been accepted for review by the U.
S. Food & Drug Administration (FDA), and could be approved before the end of the year.
The Swiss drugmaker said the FDA has accepted the company's biologics license application and has granted priority review for crizanlizumab, shortening the review period to six months from the standard ten months.
Sickle cell disease is a debilitating inherited genetic blood disorder making blood cells and blood vessels stickier than usual, causing clusters that reduce and block the flow of blood and oxygen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
S. Food & Drug Administration (FDA), and could be approved before the end of the year.
The Swiss drugmaker said the FDA has accepted the company's biologics license application and has granted priority review for crizanlizumab, shortening the review period to six months from the standard ten months.
Sickle cell disease is a debilitating inherited genetic blood disorder making blood cells and blood vessels stickier than usual, causing clusters that reduce and block the flow of blood and oxygen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.